Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)Monday, June 22, 2020 6:30 am ET Will Merck take IMM to China for this expedition?
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.005(1.09%) |
Mkt cap ! $552.8M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 48.5¢ | 46.0¢ | $1.287M | 2.727M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 147898 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 260072 | 5 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
46.8¢ |
Change
0.005 ( 0.97 %) |
||||
| Open | High | Low | Volume | ||
| 48.0¢ | 48.0¢ | 46.3¢ | 457961 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| IMM (ASX) Chart |